Amgen Inc. (AMGN) Reached the 52-Week High of $63.69
Amgen Inc. discovers, develops and delivers innovative human therapeutics. Amgen Inc. has a market cap of $55.83 billion; its shares were traded at around $63.69 with a P/E ratio of 12.3 and P/S ratio of 3.7. The dividend yield of Amgen Inc. stocks is 1.8%. Amgen Inc. had an annual average earnings growth of 16.4% over the past 10 years. GuruFocus rated Amgen Inc. the business predictability rank of 3-star.
On October 24, Amgen Inc. reported total revenue increased 3 percent during the third quarter of 2011 to$3,944 million versus $3,816 million in the third quarter of 2010. Total product sales increased 3 percent in the third quarter of 2011 to $3,877 million versus $3,759 million in the third quarter of 2010.
In November, Chairman of the Board and CEO Kevin W. Sharer, Executive Vice President Operations Fabrizio Bonanni, and Senior Vice President and CCO Anna Richo sold shares of AMGN stock. Senior Vice President Human Resources Brian M. Mcnamee sold 1,000 shares in September.
American Electric Power Company (AEP) Reached the 52-Week High of $41.57
American Electric Power Company has a market cap of $20.07 billion; its shares were traded at around $41.57 with a P/E ratio of 13.5 and P/S ratio of 1.3. The dividend yield of American Electric Power Company stocks is 4.5%. American Electric Power Company had an annual average earnings growth of 2% over the past five years.
On Oct. 26, American Electric Power reported 2011 third-quarter earnings, prepared in accordance with Generally Accepted Accounting Principles (GAAP), of $928 million or $1.93 per share, compared with $555 million or $1.16 per share for third-quarter 2010. Ongoing earnings (earnings excluding special items) for third-quarter 2011 were $566 million or $1.17 per share, compared with $552 million or $1.15 per share in third-quarter 2010.
In August, Director James F. Cordes bought 2,000 shares of AEP stock.
Intuitive Surgical Inc. (ISRG) Reached the 52-Week High of $457.66
Intuitive Surgical Inc. designs and manufactures the da Vinci Surgical System. Intuitive Surgical Inc. has a market cap of $17.85 billion; its shares were traded at around $457.66 with a P/E ratio of 39.6 and P/S ratio of 12.6. Intuitive Surgical Inc. had an annual average earnings growth of 48.9% over the past five years.
On October 18, Intuitive Surgical Inc. reported third quarter of 2011 revenue of $447 million, up 30% compared with $344 million for the third quarter of 2010. Third quarter of 2011 net income increased 41% to $122 million, or $3.05 per diluted share, from $87 million, or $2.14 per diluted share for the third quarter of 2010.
This month, Senior Vice Presidnet Product Development Salvatore Brogna sold 21,073 shares of ISRG. Chairman of the Board Lonnie M. Smith, Executive Vice President da Vinci WW Sales & Mktg Jerome J. Mcnamara, Director Floyd D. Loop, Md., and Director Alan J. Levy sold shares in October.
Marsh & McLennan Cos. (MMC) Reached the 52-Week High of $31.74
Marsh & McLennan is primarily a holding company which, through its subsidiaries and affiliates, provides clients with analysis, advice and transactional capabilities in the fields of risk and insurance services, investment management and consulting. Marsh & McLennan Cos. has a market cap of $17.08 billion; its shares were traded at around $31.74 with a P/E ratio of 18.5 and P/S ratio of 1.5. The dividend yield of Marsh & McLennan Cos. stocks is 2.8%. Marsh & McLennan Cos. had an annual average earnings growth of 26.6% over the past five years.
Marsh & McLennan Cos. recently reported results for the third quarter of 2011. Consolidated revenue in the third quarter of 2011 was $2.8 billion, an increase of 11 percent from the third quarter of 2010, or 5 percent on an underlying basis. Income from continuing operations, which includes a charge of $72 million related to the early extinguishment of debt, was $133 million, or $.23 per share, in the third quarter.
In November, President and CEO Marsh Peter Zaffino, President and CEO MMC Brian Duperreault, Senior Vice President, Chief HR and Communications Officer Orlando D. Ashford, and Senior Vice President, Chief Risk & Compliance Officer E. Scott Gilbert sold shares of MMC stock.
Celgene Corp. (CELG) Reached the 52-Week High of $67.32
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $29.89 billion; its shares were traded at around $67.32 with a P/E ratio of 21.7 and P/S ratio of 8.2.
On October 27, Celgene Corporation reported Non-GAAP net product sales of $1,218 million for the third quarter of 2011, a 38 percent increase from the same period in 2010. Non-GAAP net income for the third quarter of 2011 increased 34 percent to $469 million compared to $350 million in the third quarter of 2010. For the same periods, Non-GAAP diluted earnings per share increased 36 percent to $1.02 from $0.75. Based on U.S. GAAP, Celgene reported third quarter 2011 net product sales of $1,219 million and net income of $373 million or $0.81 per diluted share. For the third quarter of 2010, net product sales were $886 million and net income was $281 million or $0.60 per diluted share.
This month, Director Ernest Mario bought 2,000 shares of CELG stock. CFO Jacqualyn A. Fouse bought shares in November. Director Rodman L. Drake bought shares in October.